Martina Garau - OHE

We found for

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Market Access

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Policy Options for Formulary Development in Middle-income Countries

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Improving Efficiency and Resource Allocation in Future Cancer Care

Obstructive Sleep Apnoea: Health Economics Report

Exploring the Interdependencies of Research Funders in the UK

Exploring the link between health and wealth in decision making

Multi-Criteria Decision Analysis to Value Orphan Medicines

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Exploring the Interdependency between Public and Charitable Medical Research

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

01
02
03

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Policy Options for Formulary Development in Middle-income Countries

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Improving Efficiency and Resource Allocation in Future Cancer Care

Obstructive Sleep Apnoea: Health Economics Report

Exploring the Interdependencies of Research Funders in the UK

Exploring the link between health and wealth in decision making

Multi-Criteria Decision Analysis to Value Orphan Medicines

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Exploring the Interdependency between Public and Charitable Medical Research

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society

Share on Mastodon